Skip to main content Skip to main navigation menu Skip to site footer

Prostate acinar adenocarcinoma: a comparative study of Her-2 and Ki-67 expression on Gleason patterns

  • Ika Pawitra Miranti ,
  • Hermawan Istiadi ,
  • Putri Ajeng Ayu Larasati ,
  • Indra Wijaya ,
  • Dik Puspasari ,
  • Vega Karlowee ,


Background: Prostate cancer is one the most common malignancy in men worldwide, and acinar adenocarcinoma is the most prevalent one. Gleason score and grade group is recently used to predict the therapy and prognosis based on Gleason pattern. Her-2 and Ki-67 are markers that are widely studied in breast cancer, but their role in prostate cancer is still unclear. Her-2 is a transmembrane protein involved in oncogenesis. We hope by using the basic determinant Gleason pattern to analyze the expression of these two markers, it will contribute to understand its carcinogenesis and prognosis. The aim of the study is to determine the expression of Her-2 and Ki-67 in Gleason grade of prostate acinar adenocarcinoma.

Methods: An analytic observational study with cross-sectional design was done using 31 paraffin-embedded tissues of prostate acinar adenocarcinoma from the Anatomic Pathology Laboratory of Dr. Kariadi General Hospital, focusing on 48 areas classified into pattern 3, 4, and 5. Immunohistochemical staining was performed using Her-2 and Ki-67 antibodies to all tissues and the datas were analyzed using the Kruskal Wallis test and the Spearman test.

Results: There are significant differences and correlations between the expression of Ki-67 and Gleason grade, but there are neither significant differences nor correlation between Her-2 expression and Gleason grade.

Conclusion: Her-2 expression is almost the same among Gleason grade as basic determinant of prostate acinar adenocarcinoma


  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  2. The Union International Cancer Control. New Global Cancer Data: GLOBOCAN 2018 | UICC. Geneva, Switzerland, 12 Sept 2018 [Internet]. 2018;(September):1. Available from:
  3. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res. 2009;53(2):171–84.
  4. Indonesian Ministry of Health. InfoDATIN February 4-World Cancer Day [Internet]. [cited 2019 Jul 16]. Available from:
  5. Ro JY, Shen S, Zhai Q, Ayala A. ADVANCES IN SURGICAL PATHOLOGY PROSTATE CANCER. Cagle P, Allen T, editors. Philadelphia: Wolters Kluwer Health | Lippincott Williams & Wilkins; 2012. 4 p.
  6. Sharifi N, Salmaninejad A, Ferdosi S, Bajestani AN, Khaleghiyan M, Estiar MA, et al. HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method. Oncol Lett [Internet]. 2016 Dec [cited 2018 Sep 8];12(6):4651–8. Available from: doi: 10.3892/ol.2016.5235
  7. Verma R, Gupta V, Jagjeet S, Monica V, Gopal G, Gupta S, et al. Significance of p53 and ki-67 expression in prostate cancer. Urol Ann. 2015;4:488–493.
  8. Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, et al. Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort. PLoS One. 2017;12(11):e018652.
  9. World Health Organization. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours. 2016. 138–162 p.
  10. Mardiana N, Susilo I. Relationship of Her-2 / Neu Expression, Gleason Score and Bone Metastases in Prostate Adenocarcinoma. 2012;22(2):45–50.
  11. Chen N, Zhou Q. The evolving Gleason grading system. Chinese J Cancer Res. 2016;28(1):58–64. doi: 10.3978/j.issn.1000-9604.2016.02.04
  12. Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, et al. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology. 2006;68(1):110–5.
  13. Signoretti S. Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer. J Natl Cancer Inst. 2000;92(23):1918–25.
  14. Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BVS, Kaufman RP, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer. 1997;79(11):2162–70.<2162::AID-CNCR14>3.0.CO;2-U
  15. Murray NP, Reyes E, Tapia P, Badínez L, Orellana N. Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications—An Immunocy. Bone Marrow Res. 2012;2012:1–9.
  16. Morote J, De Torres I, Caceres C, Vallejo C, Schwartz S, Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer. 1999;84(4):421–5.<421::AID-IJC16>3.0.CO;2-9
  17. Fisher G, Yang ZH, Kudahetti S, Møller H, Scardino P, Cuzick J, et al. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer. 2013;2:271–7.
  18. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol. 2005;18(3):374–81.
  19. Vis AN, Van Rhijn BWG, Noordzij MA, Schröder FH, Van Der Kwast TH. Value of tissue markers p27kip1, MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol. 2002;197(2):148–54.

How to Cite

Miranti, I. P., Istiadi, H., Larasati, P. A. A., Wijaya, I., Puspasari, D., & Karlowee, V. (2021). Prostate acinar adenocarcinoma: a comparative study of Her-2 and Ki-67 expression on Gleason patterns. Bali Medical Journal, 10(2), 677–682.




Search Panel